News

Arjuna targets curcumin at Europe

13 Nov 2015

Arjuna Natural Extracts says it is targeting the European market with its BCM-95 Curcumin, an all-natural patented formulation of turmeric extract that the company says can help mitigate symptoms of depression and anxiety.

Arjuna Natural Extracts says it is targeting the European market with its BCM-95 Curcumin, an all-natural patented formulation of turmeric extract. This ingredient can, the company says, help mitigate symptoms of depression and anxiety, according to a recent clinical study, further backed by nearly two dozen previous studies supporting the health benefits of BCM-95 Curcumin extract.

“Curcumin’s positive antidepressant and anti-anxiety effects are likely due to its ability to normalize specific physiological pathways,” said Adrian Lopresti, of Murdoch University, Australia, who published the study. “It appears to elevate neurotransmitters such as serotonin, while lowering stress hormones, such as cortisol, and is a potent antioxidant and anti-inflammatory. Curcumin also provides protection to the brain.”

Depression is a common, treatable disorder that continues to remain under-detected globally, Arjuna believes, with health surveys indicating that major depression is experienced by 10-15% of people in their lifetime. Depression is, the company says, caused by multiple factors and the success rate of current treatment is only 20-40%., going on to note that many treatments are associated with side effects from long-term use, including anxiety, thoughts of suicide, insomnia, weight gain and sexual dysfunction.

Curcumin is said to work simultaneously on multiple pathways associated with depression, and Arjuna says it is considered as the most promising therapeutic target to treat depressive behaviour.